PhosPrint

PhosPrint develops laser bioprinting systems for ex vivo and in vivo use along with specialized protocols for cell isolation, expansion and printing towards regenerative medicine applications. The company was founded in 2019 as a Private Company (IKE) registered in Greece, and it is a spinoff of the Institute of Communication and Computer Systems of the National Technical University of Athens (ICCS/NTUA).

The company has a fully functional pre-industrial laser bioprinter which has been extensively tested, optimized and validated in the surgery room by surgeons. It has secured IP (5 patent families) and trade secrets (manufacturing know-how), protocols for cell isolation and expansion, and proprietary pre-clinical data.

PhosPrint is currently in the preclinical stage, soon to move to first-in-humans clinical trial of its proof-of-concept indication of bladder reconstruction. Operations so far have been funded primarily from EU Grants and Projects with most notable the receipt of a €2mm EIC Grant First Award and it is currently going through a seed round to raise €0.8mm.